Bioanalytical Systems, Inc. (NASDAQ:BASI) COO Daniel Thomas Oakley purchased 5,000 shares of the firm’s stock in a transaction dated Thursday, August 29th. The shares were acquired at an average cost of $2.69 per share, with a total value of $13,450.00. Following the completion of the purchase, the chief operating officer now directly owns 36,046 shares in the company, valued at $96,963.74. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Daniel Thomas Oakley also recently made the following trade(s):

  • On Thursday, September 5th, Daniel Thomas Oakley purchased 10,500 shares of Bioanalytical Systems stock. The shares were acquired at an average cost of $3.45 per share, with a total value of $36,225.00.
  • On Friday, August 23rd, Daniel Thomas Oakley purchased 2,594 shares of Bioanalytical Systems stock. The shares were acquired at an average cost of $2.77 per share, with a total value of $7,185.38.
  • On Friday, June 14th, Daniel Thomas Oakley purchased 7,500 shares of Bioanalytical Systems stock. The shares were acquired at an average cost of $1.99 per share, with a total value of $14,925.00.

Shares of BASI traded down $0.11 during mid-day trading on Friday, hitting $3.32. 62,535 shares of the company’s stock were exchanged, compared to its average volume of 52,781. Bioanalytical Systems, Inc. has a 52 week low of $1.18 and a 52 week high of $3.45. The company has a 50-day simple moving average of $2.31 and a 200 day simple moving average of $2.03. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.67 and a quick ratio of 0.61.

Bioanalytical Systems (NASDAQ:BASI) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.04) earnings per share for the quarter. The business had revenue of $10.86 million for the quarter. Bioanalytical Systems had a negative return on equity of 7.90% and a negative net margin of 3.38%.

Separately, ValuEngine cut shares of Bioanalytical Systems from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th.

A hedge fund recently raised its stake in Bioanalytical Systems stock. Renaissance Technologies LLC raised its holdings in shares of Bioanalytical Systems, Inc. (NASDAQ:BASI) by 7.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 253,001 shares of the company’s stock after acquiring an additional 18,120 shares during the quarter. Renaissance Technologies LLC owned approximately 2.46% of Bioanalytical Systems worth $506,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.21% of the company’s stock.

About Bioanalytical Systems

Bioanalytical Systems, Inc provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products.

Featured Story: What are the benefits of a balanced fund?

Insider Buying and Selling by Quarter for Bioanalytical Systems (NASDAQ:BASI)

Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with MarketBeat.com's FREE daily email newsletter.